Page 5 - Serum Institute

Serum to have 200 mn doses of AstraZeneca coronavirus vaccine ready by Jan

Pune company recruits over 1,600 participants in India for phase 3 trials of Covishield.

Serum Institute to manufacture 200 mn doses of Covid-19 vaccine

A further collaboration among the Serum Institute of India, Gavi and the Bill and Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 mn doses of Covid-19 vaccines

Top headlines: RIL offers Amazon stake in retail arm, SC relief on NPAs

From Reliance reportedly in talks to sell stake in retail to Amazon, IAF inducting Rafales to Serum Institute pausing Covid vaccine trial, Business Standard brings you top news of the evening

Covid-19: Serum Institute puts Oxford vaccine's India trials on hold

Serum Institute of India (SII) on Thursday said it is pausing clinical trials of AstraZeneca Oxford COVID-19 vaccine candidate in the country. Earlier this week, AstraZeneca said it had paused the trials because of 'an unexplained illness' in a participant in the study. However, SII on Wednesday said it was continuing with the trials and had not faced any issues. SII's latest announcement also comes against the backdrop of the central drug regulator DCGI issuing a show-cause notice to SII for not informing it about AstraZeneca pausing the clinical trials of the Oxford vaccine candidate in other countries. "We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials," SII said in a statement. The Pune-based vaccine maker also said it is following instructions of the Drugs Controller General of India (DCGI), it added. In the show-cause notice, DCGI V G Somani had asked SII as to why the permission granted for conducting phase 2 and 3 clinical trial

DCGI issues notice to Serum Institute over Oxford's Covid trial suspension

The DGCI sought an immediate reply saying else "it shall be construed that you have no explanation to offer and action deemed fit will be taken against you"

Vaccine will be available only after trials are successful: Serum Institute

Refutes media claims on vaccine to be available in 73 days

Serum Institute to partner with Gates Foundation to make Covid-19 vaccine

BENGALURU (Reuters) - The Serum Institute of India said it will partner with the Bill & Melinda Gates Foundation and international vaccine alliance GAVI to manufacture and deliver 100 million COVID-19 vaccine doses for India and other low- and middle-income nations as early as 2021.

Serum Institute gets nod for Phase-2 and 3 trials of Oxford's Covid vaccine

While the price of the vaccine hasn't yet been decided, the firm said it would like to keep it under Rs 1,000

'Our sort of moment': Indian billionaires bet big in Covid-19 vaccine race

Serum Institute, the world's largest vaccine producer, has announced a plan to make hundreds of millions of doses of an unproven inoculation. 'I hope we don't go in too deep,' says CEO Adar Poonawalla

India's 'vaccine capability' to be crucial in Covid-19 fight: UK envoy

British High Commissioner Philip Barton also said India is "really important" to the UK in meeting the Covid-19 challenges and getting through the pandemic

Serum Institute risks making Covid vaccine before trial at new $100 mn unit

AstraZeneca deal with SII is for supply of a billion doses, with a commitment to provide 400 mn before 2020-end. If all goes well, India could have its first set of Covid-19 vaccines by end of year

Not just bigwigs, Mid-rung local players join coronavirus vaccine race

With vaccines of some firms already in animal trial phase, developers say that if all goes well, India could have a vaccine by next year

Serum Institute to launch new vaccines; foray in Europe, US markets by 2020

On Tuesday, Serum Institute launched a rotavirus vaccine to prevent rabies